However, a small number of papers argue the opposite and suggest that high levels of GREM1 are prognostic of less aggressive tumor phenotypes and improved patient outcomes in both pancreatic adenocarcinoma (27) and colorectal cancer (28) (reviewed in (29)). This evidence concerns the gene GREM1 and neoplasm.